Skip to search formSkip to main contentSkip to account menu

UK 453,061

Known as: UK453061, UK 453061, UK-453061 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Objective:A 96-week clinical study was planned to estimate the antiviral activity and safety of lersivirine in treatment-naive… 
2012
2012
OBJECTIVE A 96-week clinical study was planned to estimate the antiviral activity and safety of lersivirine in treatment-naive… 
2012
2012
AIMS To investigate the effect of inhibitors of cytochrome P450 (CYP) 3A4 and glucuronidation (UGT2B7) on the pharmacokinetics of… 
Review
2010
Review
2010
HIV type-1 (HIV-1) non-nucleoside reverse transcriptase inhibitors (NNRTIs) are key drugs of highly active antiretroviral therapy… 
Highly Cited
2010
Highly Cited
2010
ABSTRACT The nonnucleoside reverse transcriptase inhibitors (NNRTIs) are key components of highly active antiretroviral therapy… 
2009
2009
Objective:To investigate the effects on viral load and assess dose–response relationships, pharmacokinetics, safety and… 
Highly Cited
2009
Highly Cited
2009
2009
2009
The requirements for safe testing of pharmaceuticals in humans places substantial emphasis on the translation of safety testing… 
Review
2008
Review
2008
Efavirenz non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy or boosted protease inhibitor (PI)-based therapy… 
2008
2008
1. UK-453,061 is a novel second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Following intravenous bolus…